Ken Griffin Bolt Biotherapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,367,511 shares of BOLT stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,367,511
Previous 2,415,728
2.0%
Holding current value
$1.61 Million
Previous $3.38 Million
47.52%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BOLT
# of Institutions
37Shares Held
22.8MCall Options Held
0Put Options Held
0-
Tang Capital Management LLC San Diego, CA3.81MShares$2.59 Million0.35% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.52MShares$2.39 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.75MShares$1.87 Million0.11% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA1.89MShares$1.29 Million1.28% of portfolio
-
Newtyn Management, LLC New York, NY1.36MShares$926,9990.22% of portfolio
About Bolt Biotherapeutics, Inc.
- Ticker BOLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,641,500
- Market Cap $25.6M
- Description
- Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...